News

Regeneron Pharmaceuticals (REGN) Announces Approval of Dupixent in the US
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc.
The Pharma Letter21h
The week in pharma: action, reaction and insight – week to July 4
US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...
Taiwan News11h
Atopic Dermatitis Therapeutic Market 2025: Reshaping Business Models and Digital Transformation Through 2032
The atopic dermatitis therapeutics market is poised for steady growth, with revenues projected to rise from USD 15.43 billion in 2024 to USD 29.5 billion by 2033. This reflects a compound annual ...